Cases and


Webinar “Highlights of the next-in-class drugs development”

The development of pharmacologically similar agents and improved analogues of innovative drugs (next-in-class) is one of the target directions in evolution of Russian pharmaceutical industry under the “Pharma 2020” program.

What will we discuss in Webinar?

  • the advantages and risks of next-in-class drug development

  • specifics of these drugs clinical trials program planning

  • the applicability of adaptive designs using  in clinical trials of the next-in-class drug on the example of different pharmacological classes

For whom?

For drug developers, pharmaceutical and biotech companies, participants in the clinical trial market, doctors. 


Natalia Vostokova, IPHARMA Chief Operating Officer

Julia Tahtenberg, IPHARMA Medical Director